Real-world systemic sequential therapy with regorafenib for recurrent hepatocellular carcinoma: analysis of 93 cases from a single center
- Resource Type
- article
- Authors
- Qingwei Zhu; Wei Rao; Junyu Huo; Zixiang Li; Song Wang; Wensheng Qiu; Ge Guan; Yang Xin; Ning Fan; Jinzhen Cai; Liqun Wu
- Source
- BMC Gastroenterology, Vol 23, Iss 1, Pp 1-11 (2023)
- Subject
- Hepatocellular carcinoma
Regorafenib
Combination therapy
Real-world research
Diseases of the digestive system. Gastroenterology
RC799-869
- Language
- English
- ISSN
- 1471-230X
Abstract Background Regorafenib is an oral multikinase inhibitor and became the first second-line systemic treatment for hepatocellular carcinoma (HCC) following the phase III RESORCE trial. This single-center study retrospectively analyzed the clinical data and follow-up results of patients with recurrent HCC treated with regorafenib and discussed the prognostic factors to provide guidance for clinical treatment. Methods Ninety-three recurrent HCC patients were enrolled in the research and follow up from December 2017 to December 2020. Clinical and pathological data were collected. SPSS software v26.0 was used (Chicago, IL, USA) for statistical analysis. A two-sided P